New treatment approaches in primary central nervous system lymphoma

Carole Soussain, Khê Hoang-Xuan, Nancy Doolittle

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The treatment of PCNSL differs from that of systemic NHL because chemotherapeutic agents need to cross the BBB in PCNSL. Inadequate drug delivery to the tumor is the main factor underlying unsatisfactory responses in patients with PCNSL, and this prevents the use of standard treatments for NHL, such as CHOP-like chemotherapy containing an anthracycline. The lymphoma itself does not appear to be specifically resistant. Because many drugs are substrates for transporter molecules such as P-glycoprotein, multidrug-resistance-associated protein, and organic anion-transporting polypeptides, several candidate drugs are substrates or inhibitors of these carrier proteins. Preclinical studies are ongoing. Future leads include lipid-soluble analogs or prodrugs that are not substrates for the barrier efflux system. Novel approaches with proven feasibility are currently limited to high-dose chemotherapy with hematopoietic rescue and BBB disruption that possibly circumvent the hurdle represented by the BBB. The possible benefit of adding rituximab to first-line treatment remains to be demonstrated in the specific setting of PCNSL. Neurotoxicity also must be better controlled, possibly by using compounds that protect the brain without undermining treatment efficacy.

Original languageEnglish (US)
Pages (from-to)719-728
Number of pages10
JournalHematology/Oncology Clinics of North America
Volume19
Issue number4
DOIs
StatePublished - Aug 2005
Externally publishedYes

Fingerprint

Lymphoma
Central Nervous System
Pharmaceutical Preparations
Multidrug Resistance-Associated Proteins
Drug Therapy
Anthracyclines
Prodrugs
P-Glycoprotein
Anions
Carrier Proteins
Therapeutics
Lipids
Peptides
Brain
Neoplasms
Rituximab

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

New treatment approaches in primary central nervous system lymphoma. / Soussain, Carole; Hoang-Xuan, Khê; Doolittle, Nancy.

In: Hematology/Oncology Clinics of North America, Vol. 19, No. 4, 08.2005, p. 719-728.

Research output: Contribution to journalArticle

Soussain, Carole ; Hoang-Xuan, Khê ; Doolittle, Nancy. / New treatment approaches in primary central nervous system lymphoma. In: Hematology/Oncology Clinics of North America. 2005 ; Vol. 19, No. 4. pp. 719-728.
@article{152f5860f12c47d28ae01126372c0dcf,
title = "New treatment approaches in primary central nervous system lymphoma",
abstract = "The treatment of PCNSL differs from that of systemic NHL because chemotherapeutic agents need to cross the BBB in PCNSL. Inadequate drug delivery to the tumor is the main factor underlying unsatisfactory responses in patients with PCNSL, and this prevents the use of standard treatments for NHL, such as CHOP-like chemotherapy containing an anthracycline. The lymphoma itself does not appear to be specifically resistant. Because many drugs are substrates for transporter molecules such as P-glycoprotein, multidrug-resistance-associated protein, and organic anion-transporting polypeptides, several candidate drugs are substrates or inhibitors of these carrier proteins. Preclinical studies are ongoing. Future leads include lipid-soluble analogs or prodrugs that are not substrates for the barrier efflux system. Novel approaches with proven feasibility are currently limited to high-dose chemotherapy with hematopoietic rescue and BBB disruption that possibly circumvent the hurdle represented by the BBB. The possible benefit of adding rituximab to first-line treatment remains to be demonstrated in the specific setting of PCNSL. Neurotoxicity also must be better controlled, possibly by using compounds that protect the brain without undermining treatment efficacy.",
author = "Carole Soussain and Kh{\^e} Hoang-Xuan and Nancy Doolittle",
year = "2005",
month = "8",
doi = "10.1016/j.hoc.2005.05.007",
language = "English (US)",
volume = "19",
pages = "719--728",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - New treatment approaches in primary central nervous system lymphoma

AU - Soussain, Carole

AU - Hoang-Xuan, Khê

AU - Doolittle, Nancy

PY - 2005/8

Y1 - 2005/8

N2 - The treatment of PCNSL differs from that of systemic NHL because chemotherapeutic agents need to cross the BBB in PCNSL. Inadequate drug delivery to the tumor is the main factor underlying unsatisfactory responses in patients with PCNSL, and this prevents the use of standard treatments for NHL, such as CHOP-like chemotherapy containing an anthracycline. The lymphoma itself does not appear to be specifically resistant. Because many drugs are substrates for transporter molecules such as P-glycoprotein, multidrug-resistance-associated protein, and organic anion-transporting polypeptides, several candidate drugs are substrates or inhibitors of these carrier proteins. Preclinical studies are ongoing. Future leads include lipid-soluble analogs or prodrugs that are not substrates for the barrier efflux system. Novel approaches with proven feasibility are currently limited to high-dose chemotherapy with hematopoietic rescue and BBB disruption that possibly circumvent the hurdle represented by the BBB. The possible benefit of adding rituximab to first-line treatment remains to be demonstrated in the specific setting of PCNSL. Neurotoxicity also must be better controlled, possibly by using compounds that protect the brain without undermining treatment efficacy.

AB - The treatment of PCNSL differs from that of systemic NHL because chemotherapeutic agents need to cross the BBB in PCNSL. Inadequate drug delivery to the tumor is the main factor underlying unsatisfactory responses in patients with PCNSL, and this prevents the use of standard treatments for NHL, such as CHOP-like chemotherapy containing an anthracycline. The lymphoma itself does not appear to be specifically resistant. Because many drugs are substrates for transporter molecules such as P-glycoprotein, multidrug-resistance-associated protein, and organic anion-transporting polypeptides, several candidate drugs are substrates or inhibitors of these carrier proteins. Preclinical studies are ongoing. Future leads include lipid-soluble analogs or prodrugs that are not substrates for the barrier efflux system. Novel approaches with proven feasibility are currently limited to high-dose chemotherapy with hematopoietic rescue and BBB disruption that possibly circumvent the hurdle represented by the BBB. The possible benefit of adding rituximab to first-line treatment remains to be demonstrated in the specific setting of PCNSL. Neurotoxicity also must be better controlled, possibly by using compounds that protect the brain without undermining treatment efficacy.

UR - http://www.scopus.com/inward/record.url?scp=23244444183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23244444183&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2005.05.007

DO - 10.1016/j.hoc.2005.05.007

M3 - Article

C2 - 16083832

AN - SCOPUS:23244444183

VL - 19

SP - 719

EP - 728

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 4

ER -